Antibody–drug conjugates for cancer therapy

Published on Jun 1, 2016in Lancet Oncology33.752
· DOI :10.1016/S1470-2045(16)30030-4
Anish Thomas36
Estimated H-index: 36
,
Beverly A Teicher1
Estimated H-index: 1
+ 0 AuthorsRaffit Hassan58
Estimated H-index: 58
Sources
Abstract
Summary Antibody–drug conjugates are monoclonal antibodies conjugated to cytotoxic agents. They use antibodies that are specific to tumour cell-surface proteins and, thus, have tumour specificity and potency not achievable with traditional drugs. Design of effective antibody–drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector molecules, and conjugation of the monoclonal antibody to cytotoxic agents. Substantial advances in all these aspects in the past decade have resulted in regulatory approval of ado-trastuzumab emtansine and brentuximab vedotin for clinical use. Several promising antibody–drug conjugates are now in late-phase clinical testing. Ongoing efforts are focused on identifying better targets, more effective cytotoxic payloads, and further improvements in antibody–drug linker technology. Improved understanding of the mechanistic basis of antibody–drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy.
📖 Papers frequently viewed together
726 Citations
154 Citations
1,963 Citations
References72
Newest
#1George R. Blumenschein (University of Texas MD Anderson Cancer Center)H-Index: 69
#2Raffit Hassan (NIH: National Institutes of Health)H-Index: 58
Last. Johanna C. Bendell (Sarah Cannon Research Institute)H-Index: 69
view all 11 authors...
2509Background: AR (BAY 94-9343) comprises a novel fully human anti-mesothelin IgG1 antibody conjugated to the maytansinoid tubulin inhibitor DMR. A phase I study was conducted in patients (pts) with advanced solid tumors. Methods: Eligible pts with solid tumors refractory to standard treatment, adequate organ function, and ECOG performance status (PS) ≤ 1 were enrolled. AR was administered IV on 2 schedules: every 21 days (q3w) in 45 pts (21 mesothelioma [Meso], 9 pancreatic, 5 breast, 4 ovaria...
23 CitationsSource
#1Raffit Hassan (NIH: National Institutes of Health)H-Index: 58
#2Christine Alewine (LMB: Laboratory of Molecular Biology)H-Index: 10
Last. Ira Pastan (LMB: Laboratory of Molecular Biology)H-Index: 191
view all 3 authors...
Immunotoxins are targeted anticancer therapeutics that kill cancer cells using a cytotoxic bacterial toxin payload. Their development for use in solid tumor malignancies was delayed due to issues with their immunogenicity and limited therapeutic window. However, new research has rejuvenated the field. Coadministration with a lymphocyte-depleting regimen of pentostatin and cyclophosphamide can delay antidrug antibody formation, increasing the number of treatment cycles that patients can receive a...
23 CitationsSource
#1Bishoy Faltas (Cornell University)H-Index: 17
#2David M. GoldenbergH-Index: 129
Last. Scott T. Tagawa (Cornell University)H-Index: 50
view all 10 authors...
Abstract Patients with metastatic, platinum-resistant urothelial carcinoma (PRUC) have no Food and Drug Administration–approved therapies. The response rates to second-line chemotherapy have generally been ClinicalTrials.gov identifier NCT01631552 ) with the novel antibody–drug conjugate, sacituzumab govitecan (IMMU-132). This antibody–drug conjugate comprises the active metabolite of irinotecan, SN-38, conjugated to an anti-Trop-2 antibody. Trop-2 is widely expressed in ≤ 83% of urothelial carc...
46 CitationsSource
#1Naval Daver (University of Texas MD Anderson Cancer Center)H-Index: 54
#2Hagop M. Kantarjian (University of Texas MD Anderson Cancer Center)H-Index: 232
Last. Gautam Borthakur (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 18 authors...
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
47 CitationsSource
#1Hervé Dombret (Paris Diderot University)H-Index: 93
#2Claude Gardin (Paris Diderot University)H-Index: 48
Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape should ultimately lead to more subset-specific AML therapies, ideally tailored to each patient's disease. Although a growing number of distinct AML subsets have been increasingly characterized, patient management has remained disappointingly uniform. If one excludes acute promyelocytic leukemia, current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantat...
248 CitationsSource
#1Philipp Müller (University of Basel)H-Index: 15
#2Matthias Kreuzaler (University of Basel)H-Index: 7
Last. Alfred Zippelius (University of Basel)H-Index: 47
view all 15 authors...
Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer (WSG-ADAPT trial) and in a HER2-expressing orthotopic tumor model. In the latter, despite primary resistance to immunotherapy, combined treatment with T-DM1 and anti–CTLA-4/PD-1 (cytotoxic T lymphocyte–associated prote...
148 CitationsSource
#1Boris Shor (Pfizer)H-Index: 4
#2Hans-Peter Gerber (Pfizer)H-Index: 18
Last. Puja Sapra (Pfizer)H-Index: 19
view all 3 authors...
Abstract Calicheamicin is a DNA-damaging agent that, following intracellular activation, binds to DNA in the minor groove and introduces double-strand DNA breaks, leading to G2/M arrest and subsequent cell death. Importantly, the mechanism of action of calicheamicin is fundamentally different from the tubulin-binding class of cytotoxics targeting the mitotic spindle, which represent the most common class of payloads for antibody–drug conjugates (ADCs) currently undergoing clinical development. S...
70 CitationsSource
The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient survival. Patient-derived xenograft (PDX) tumors serve as excellent models to study tumor biology and characterize TICs. Increased expression of delta-like 3 (DLL3) was discovered in SCLC and LCNEC PDX t...
281 CitationsSource
#1Shyra Gardai (Seattle Genetics)H-Index: 5
#2Angela Epp (Seattle Genetics)H-Index: 3
Last. Che-Leung Law (Seattle Genetics)H-Index: 20
view all 3 authors...
Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate (ADC) directed against CD30. It consists of an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent. Brentuximab vedotin is approved for the treatment of relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin antitumor activity is due to the binding of the ADC to CD30-expressing cells, followed by internalization, and release of MMAE ...
14 CitationsSource
#1Hossein Borghaei (Fox Chase Cancer Center)H-Index: 48
#2David M. O'Malley (OSU: Ohio State University)H-Index: 47
Last. Kathleen N. Moore (University of Oklahoma Health Sciences Center)H-Index: 45
view all 13 authors...
5558 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC comprising a FRα-binding antibody and potent maytansinoid, DM4. Methods: This Phase 1 trial is being conducted to determine safety, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, recommended phase 2 dose (RP2D) and evidence of activity of IMGN853 in pts with EOC or other FRa-positive solid tumors. As previously reported, the occurrence of ocular adverse events (AEs) was associated with peak drug exposur...
10 CitationsSource
Cited By176
Newest
#1Kai ChenH-Index: 3
#2Yingnan SiH-Index: 4
Last. Xiaoguang Margaret Liu (UAB: University of Alabama at Birmingham)H-Index: 7
view all 10 authors...
Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor efficacy of SSTR2 ADC were evaluated using cell li...
Source
#1Yan-Lin Ren (Nanjing Medical University)H-Index: 1
#1Yanlin Ren (Nanjing Medical University)
Last. Jianwei Zhou (Nanjing Medical University)H-Index: 43
view all 7 authors...
The overexpression of HER2 is associated with a malignant proliferation of breast cancer. In this study, we developed a non-cytotoxic JWA gene activating compound 1 (JAC1) to inhibit the proliferation of HER2-positive breast cancer cells in vitro and in vivo experimental models. JAC1 increased the ubiquitination of HER2 at the K716 site through the E3 ubiquitin ligase SMURF1 which was due to the decreased expression of NEDD4, the E3 ubiquitin ligase of SMURF1. In conclusion, JAC1 suppresses the ...
Source
#1Qian-Ni Ye (SCUT: South China University of Technology)H-Index: 1
#2Yue Wang (SCUT: South China University of Technology)H-Index: 1
Last. Jun Wang (SCUT: South China University of Technology)H-Index: 86
view all 5 authors...
Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody-mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off-target cytotoxicity. In recent years, an increasing number of biomaterials-based delivery syste...
Source
#1Efrat Luttwak (TAU: Tel Aviv University)H-Index: 2
#2A. Gurevich-Shapiro (TAU: Tel Aviv University)
Last. Irit Avivi (TAU: Tel Aviv University)H-Index: 12
view all 10 authors...
Abstract Lymphoproliferative diseases occurring during pregnancy present unique diagnostic and therapeutic challenges aiming to achieve maternal cure without impairing fetal health, growth, and survival. These goals are further complicated by the fast-paced emergence of novel therapies and their introduction as standard of care, even in newly diagnosed patients. Due to the rarity of hematological malignancies in pregnancy and the exclusion of pregnancy in almost all clinical trials, available da...
Source
Nowadays, the landscape of cancer treatments has broadened thanks to the clinical application of immunotherapeutics. After decades of failures, cancer immunotherapy represents an exciting alternative for those patients suffering from a wide variety of cancers, especially for those skin cancers, such as the early stages of melanoma. However, those cancers affecting internal organs still face a long way to success, because of the poor biodistribution of immunotherapies. Here, nanomedicine appears ...
Source
#1Marco Catalano (EPFL: École Polytechnique Fédérale de Lausanne)H-Index: 5
#2Gabriele Bassi (EPFL: École Polytechnique Fédérale de Lausanne)H-Index: 3
Last. Dario Neri (EPFL: École Polytechnique Fédérale de Lausanne)H-Index: 99
view all 9 authors...
Human tyrosinase (hTYR) and tyrosinase-related protein 1 (hTYRP1) are closely-related enzymes involved in the synthesis of melanin, which are selectively expressed in melanocytes and, in a pathological context, in melanoma lesions. We used a previously described tyrosinase inhibitor (Thiamidol™) and DNA-encoded library technology for the discovery of novel hTYR and hTYRP1 ligands, that could be used as vehicles for melanoma targeting. Performing de novo selections with DNA-encoded libraries, we ...
1 CitationsSource
#1Rebekka George (FAU: University of Erlangen-Nuremberg)
Last. Fabian MüllerH-Index: 17
view all 7 authors...
Many proteins are still routinely expressed prokaryotically in Escherichia coli, some because they are toxic to eukaryotes. Immunotoxins, which are fusion proteins of a targeting moiety and a truncated Pseudomonas exotoxin A, kill target cells by arresting protein synthesis. Thus, immunotoxins must be expressed in E. coli. Proteins expressed in E. coli are contaminated by endotoxin (also called lipopolysaccharides (LPS)). LPS binds to toll-like receptors, inducing up to life-threatening systemic...
Source
#1Tomoko Watanabe (AIST: National Institute of Advanced Industrial Science and Technology)H-Index: 1
#2Hiroaki Tateno (AIST: National Institute of Advanced Industrial Science and Technology)H-Index: 35
Human induced pluripotent stem cells (hiPSCs) are important starting materials for cell therapy products (CTPs) used for transplantation. During cell culture, hiPSCs often spontaneously undergo morphological changes and lose pluripotency. Such cells are called 'deviated cells', which are deviated from the undifferentiated state of hiPSCs, lack the expression of hiPSC markers and become positive for the early differentiation marker SSEA1 (stage-specific embryonic antigen 1, Lewis X glycan). Previ...
Source
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
Source
#1Victor YipH-Index: 7
#2M. Violet LeeH-Index: 2
Last. Ben-Quan ShenH-Index: 16
view all 6 authors...
Polatuzumab vedotin (or POLIVY®), an antibody–drug conjugate (ADC) composed of a polatuzumab monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable dipeptide linker, has been approved by the United States Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL). To support the clinical development of polatuzumab vedotin, we characterized the distribution, catabolism/metabolism, and elimination properties of polatuzumab vedotin and it...
Source